Cover Image

Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center

BACKGROUND The advent of imatinib has considerably changed the treatment of chronic myeloid leukemia (CML). Early studies demonstrated high rates of hematologic and cytogenetic responses in all phases of the disease after limited observation periods. METHODS The authors evaluated long-term outcome,...

Full description

Saved in:
Bibliographic Details
Main Authors: Lahaye, Tanja (Author) , Riehm, Birte (Author) , Berger, Ute (Author) , Paschka, Peter (Author) , Müller, Martin Christian (Author) , Kreil, Sebastian (Author) , Merx, Kirsten (Author) , Schwindel, Uwe (Author) , Schoch, Claudia (Author) , Hehlmann, Rüdiger (Author) , Hochhaus, Andreas (Author)
Format: Article (Journal)
Language:English
Published: 03 March 2005
In: Cancer
Year: 2005, Volume: 103, Issue: 8, Pages: 1659-1669
ISSN:1097-0142
DOI:10.1002/cncr.20922
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1002/cncr.20922
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/cncr.20922
Get full text
Author Notes:Tanja Lahaye, Birte Riehm, Ute Berger, Peter Paschka, Martin C. Müller, Sebastian Kreil, Kirsten Merx, Uwe Schwindel, Claudia Schoch, Rüdiger Hehlmann, Andreas Hochhaus
Description
Summary:BACKGROUND The advent of imatinib has considerably changed the treatment of chronic myeloid leukemia (CML). Early studies demonstrated high rates of hematologic and cytogenetic responses in all phases of the disease after limited observation periods. METHODS The authors evaluated long-term outcome, rates of response, and resistance in 300 patients with BCR-ABL-positive leukemias (CML in chronic phase after failure to respond to interferon-alpha [CP], n = 139; accelerated phase [AP], n = 80; myeloid blast crisis [BC], n = 76; lymphoid BC and Philadelphia chromosome-positive acute lymphoblastic leukemia, n = 5) who entered clinical trials with imatinib in a single center after an observation time of 4.5 years. RESULTS In CP, hematologic remission was achieved in 97% and major (MCR) and complete cytogenetic remission (CCR) in 61% and 49% of patients, respectively. The chance to achieve MCR was higher in patients commencing imatinib earlier in the course of CML. In AP, the median survival period after the start of imatinib was 44 months, and MCR and CCR were observed in 31% and 26% of patients, respectively. In myeloid BC, the median survival period after the start of imatinib and after diagnosis of BC was 6 and 9 months, respectively. Hematologic resistance occurred in 25%, 41%, and 92% of patients in CP, AP, and myeloid BC, respectively, and was associated with BCR-ABL mutations in 45% of patients and with clonal evolution in 58% of patients. CONCLUSIONS The data emphasized the need for a prolonged follow-up of patients treated with imatinib to define the clinical potential of the drug and to establish methods to optimize therapy.
Item Description:Gesehen am 11.05.2022
Physical Description:Online Resource
ISSN:1097-0142
DOI:10.1002/cncr.20922

Similar Items